Diabetic neuropathy: therapies on the horizon
نویسندگان
چکیده
منابع مشابه
Antiviral therapies on the horizon for influenza.
Adequate response to severe influenza infections or pandemic outbreaks requires two complementary strategies: preventive vaccination and antiviral therapy. The existing influenza drugs, M2 blockers and neuraminidase inhibitors, show modest clinical efficacy and established or potential resistance. In the past three years, several new agents have entered the clinical pipeline and already yielded...
متن کاملThe effect of date aqua extract and melatonin on diabetic neuropathy in STZ-induced diabetic rats
Introduction: Diabetes mellitus is often associated with chronic neuropathy, a condition which is due to the disturbance in the function of peripheral nervous system. Studying the effects of antioxidants in relieving neuropathy is of a great clinical importance. The aim of this study was to compare the effect of aqua extract of date and Melatonin in preventing neuropathic hyperalgesia in Strept...
متن کاملBladder, Bowel and Sexual Function/Dysfunction in Diabetic Peripheral Neuropathy: A Look Beyond the Horizon
This article was aimed at throwing light on the relatively under-researched area in diabetic peripheral neuropathy (DPN), the presence of visceropelvic disorders secondary to bladder, bowel and sexual dysfunction through a scoping overview of current research evidence. The three studies on bladder dysfunction in DPN uniformly found increased residual urine, urinary retention and slowing of nerv...
متن کاملNew therapies on the horizon for hepatitis C.
Therapy of chronic HCV infection has greatly improved in recent years with the addition of ribavirin to alpha interferon and has further improved more with the use of PEG-interferons. However, more than half of patients do not achieve lasting benefits from these therapies. The future therapeutic developments may include one or more of the following approaches: understanding the HCV genomic orga...
متن کاملTreatment options for obesity and potential therapies on the horizon.
Orlistat (Xenical, Alli) Orlistat (Xenical, Roche) is one of only two medications approved by the FDA for the treatment of obesity. A lipase inhibitor, it prevents the breakdown of dietary triglycerides to fatty acids and monoglycerides. The prescribed dose of 120 mg three times daily is taken with meals and prevents approximately 30% of ingested fat from being absorbed.6 According to a meta-an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Pharmacy and Pharmacology
سال: 2009
ISSN: 0022-3573,2042-7158
DOI: 10.1211/jpp.61.09.0002